Mumbai: Through a recent press release Drug firm Lupin recently announced the receipt of the Establishment Inspection Report (EIR) for its Pithampur (Unit 3) facility in Madhya Pradesh from the US health regulator. The inspection at the site was conducted between June 12, 2017, and June 16, 2017.
This was a Pre-approval inspection for Albuterol Sulfate Inhalation product. Lupin’s Pithampur (Unit 3) facility manufactures Dermatological Products, Dry Product Inhalers and Metered Dose Inhalers.
Commenting on the development, Nilesh Gupta, Managing Director, Lupin said, “The receipt of the EIR for our Pithampur Unit 3 is an encouraging development. This is a validation of our commitment to maintaining the highest standards in quality and compliance across our facilities.”
Read Also: Lupin gets 22 observations for MP plant
The US Food and Drug Administration (USFDA) issues an EIR to an establishment that is the subject of an FDA or FDA-contracted inspection when the agency decides to close the inspection.
Lupin is a pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
Latest posts by MD Team (see all)
- Recordati to seek Canadian approval for kidney disease drug Cystagon - April 17, 2019
- Wockhardt gets zero USFDA observations for Bioequivalence centre - April 16, 2019
- Amgen sets over Rs 15 lakh yearly price for new bone drug Evenity - April 16, 2019